ArticleHealth affairs scholar2025
What is driving 340B growth: utilization or price?
Article in Health affairs scholar, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2023, the 340B Drug Pricing Program ("340B program") saw a 24% year-over-year growth, with the Health Resources and Services Administration (HRSA), the federal agency responsible for the program, announcing that 340B discounted purchases had reached $66 billion. Despite the program's growth, size, and impact, there is little published research on the factors causing 340B growth, with different stakeholders offering divergent explanations. Program advocates contend that manufacturer price increases are the primary driver of 340B growth, while program critics argue that 340B hospitals are driving utilization. This study used price-volume-mix decomposition to examine the relative importance of price vs utilization for 340B growth using a national sample of over 28 000 National Drug Code drugs. From 2018 to 2024, utilization accounted for an average of 79.6% of 340B growth based on list price, and close to 100% of growth based on 340B discount prices. Utilization also accounted for the majority of 340B growth for the top 10 drugs reported by HRSA and for the segment of drugs with price increases above inflation. These findings show that utilization increases, not manufacturer pricing decisions, are the main driver of 340B growth, a conclusion that may have significant public policy implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.